Clinical Trial Tests D-Serine to Modify Parkinson’s Disease
SPARK NS and Haukeland University Hospital will run a randomized, double-blind, placebo-controlled Phase 2b trial of oral D-serine in...
Jon Napitupulu
Orphai’s LAM-001 Study Selected for ATS 2026 Presentation
No efficacy or safety data were released, but Orphai Therapeutics will present 24-week Phase 2a results of inhaled sirolimus...
Spyglass Pharma Begins Phase III Trials for BIM-IOL System
SpyGlass Pharma has randomized the first patients into two registrational Phase III trials, SGP-005 and SGP-006, evaluating its Bimatoprost...
Rein’s Breakthrough IPF Drug Gets Rare EU Orphan Status
Rein Therapeutics secured European orphan drug designation for LTI-03 in idiopathic pulmonary fibrosis, adding regulatory leverage to a program...
Reunion Unlocks Full RE104 PPD Phase 2 Trial Results
Reunion Neuroscience’s single-dose RE104 met the primary endpoint in the Phase 2 RECONNECT study for postpartum depression (PPD), delivering...
FDA Confirms Rexlemestrocel-L Efficacy for Back Pain Relief
Mesoblast’s first randomized Phase 3 trial in chronic discogenic low back pain reported a more than three-fold increase in...
Axsome Launches Surging Phase 3 Trial for Fibromyalgia Drug
Axsome has dosed the first patient in FORWARD, a Phase 3 randomized withdrawal trial of AXS-14 (esreboxetine) for fibromyalgia....
VapeAway Begins Clinical Study for Vaping Cessation Device
VapeAway has enrolled the first participant in CONQUER, a single‑arm, open‑label, multicenter study of its drug‑free filter and Fix+Bar...
Pioneering Phase 3 Prostate Cancer Study Doses First Patient
Telix has dosed the first U.S. patient in BiPASS, a prospective, open-label Phase 3 study evaluating whether adding 68Ga-PSMA-11...
Krystal Biotech Confirms CFTR Delivery in Phase 1 CF Study
In the highest-dose cohort of its Phase 1 CORAL-1 study, Krystal’s inhaled gene therapy KB407 achieved confirmed airway transduction...